JP2009519718A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009519718A5 JP2009519718A5 JP2008545995A JP2008545995A JP2009519718A5 JP 2009519718 A5 JP2009519718 A5 JP 2009519718A5 JP 2008545995 A JP2008545995 A JP 2008545995A JP 2008545995 A JP2008545995 A JP 2008545995A JP 2009519718 A5 JP2009519718 A5 JP 2009519718A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- antibody
- hvr
- sequence
- ox40l
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 108091007491 NSP3 Papain-like protease domains Proteins 0.000 claims 14
- 210000004027 cell Anatomy 0.000 claims 10
- 239000013598 vector Substances 0.000 claims 5
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 4
- 208000026278 immune system disease Diseases 0.000 claims 4
- 102000040430 polynucleotide Human genes 0.000 claims 3
- 108091033319 polynucleotide Proteins 0.000 claims 3
- 239000002157 polynucleotide Substances 0.000 claims 3
- 206010012438 Dermatitis atopic Diseases 0.000 claims 2
- 101000764263 Homo sapiens Tumor necrosis factor ligand superfamily member 4 Proteins 0.000 claims 2
- 206010039085 Rhinitis allergic Diseases 0.000 claims 2
- 201000010105 allergic rhinitis Diseases 0.000 claims 2
- 208000006673 asthma Diseases 0.000 claims 2
- 201000008937 atopic dermatitis Diseases 0.000 claims 2
- 210000003527 eukaryotic cell Anatomy 0.000 claims 2
- 102000051450 human TNFSF4 Human genes 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 210000001236 prokaryotic cell Anatomy 0.000 claims 2
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 208000009329 Graft vs Host Disease Diseases 0.000 claims 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 1
- 102000004473 OX40 Ligand Human genes 0.000 claims 1
- 108010042215 OX40 Ligand Proteins 0.000 claims 1
- 239000013604 expression vector Substances 0.000 claims 1
- 208000024908 graft versus host disease Diseases 0.000 claims 1
- 210000004962 mammalian cell Anatomy 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US75137705P | 2005-12-16 | 2005-12-16 | |
| PCT/US2006/062173 WO2007133290A2 (en) | 2005-12-16 | 2006-12-15 | Anti-ox40l antibodies and methods using same |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2009519718A JP2009519718A (ja) | 2009-05-21 |
| JP2009519718A5 true JP2009519718A5 (cg-RX-API-DMAC7.html) | 2011-02-10 |
Family
ID=38616368
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008545995A Withdrawn JP2009519718A (ja) | 2005-12-16 | 2006-12-15 | 抗ｏｘ４０ｌ抗体とその使用方法 |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US7812133B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP1973949A2 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2009519718A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20080080639A (cg-RX-API-DMAC7.html) |
| CN (1) | CN101374865A (cg-RX-API-DMAC7.html) |
| AR (1) | AR057253A1 (cg-RX-API-DMAC7.html) |
| AU (1) | AU2006343459A1 (cg-RX-API-DMAC7.html) |
| BR (1) | BRPI0621065A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2633602A1 (cg-RX-API-DMAC7.html) |
| CR (1) | CR10069A (cg-RX-API-DMAC7.html) |
| EC (1) | ECSP088543A (cg-RX-API-DMAC7.html) |
| IL (1) | IL191820A0 (cg-RX-API-DMAC7.html) |
| MA (1) | MA30153B1 (cg-RX-API-DMAC7.html) |
| NO (1) | NO20083147L (cg-RX-API-DMAC7.html) |
| RU (1) | RU2426744C2 (cg-RX-API-DMAC7.html) |
| TW (1) | TW200732349A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2007133290A2 (cg-RX-API-DMAC7.html) |
| ZA (1) | ZA200804868B (cg-RX-API-DMAC7.html) |
Families Citing this family (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7291331B1 (en) | 2002-09-11 | 2007-11-06 | La Jolla Institute For Allergy And Immunology | Methods of treating OX40 medicated recall immune responses |
| JP5371142B2 (ja) | 2006-07-14 | 2013-12-18 | エフ・イ−・アイ・カンパニー | マルチソース型のプラズマ集束イオン・ビーム・システム |
| MX2009009194A (es) * | 2007-02-27 | 2009-10-08 | Genentech Inc | Anticuerpos ox40 antagonistas y su uso en el tratamiento de enfermedades inflamatorias y autoinmunes. |
| US20090309617A1 (en) * | 2007-08-24 | 2009-12-17 | Ye Fang | Biosensor antibody functional mapping |
| WO2009141239A1 (en) * | 2008-05-20 | 2009-11-26 | F. Hoffmann-La Roche Ag | A pharmaceutical formulation comprising an antibody against ox40l, uses thereof |
| US8518405B2 (en) * | 2009-10-08 | 2013-08-27 | The University Of North Carolina At Charlotte | Tumor specific antibodies and uses therefor |
| WO2011073180A1 (en) | 2009-12-14 | 2011-06-23 | Ablynx N.V. | Single variable domain antibodies against ox40l, constructs and therapeutic use |
| US20120020960A1 (en) * | 2010-07-26 | 2012-01-26 | Baylor Research Institute | Thymic Stromal Lymphopoietin (TSLP) and OX40 Ligand in Cancer |
| PH12013500354B1 (en) | 2010-08-23 | 2018-10-19 | Univ Texas | Anti-ox40 antibodies and methods of using the same |
| US9845362B2 (en) | 2010-10-08 | 2017-12-19 | The University Of North Carolina At Charlotte | Compositions comprising chimeric antigen receptors, T cells comprising the same, and methods of using the same |
| AR083847A1 (es) | 2010-11-15 | 2013-03-27 | Novartis Ag | Variantes de fc (fragmento constante) silenciosas de los anticuerpos anti-cd40 |
| ME03071B (me) | 2011-04-21 | 2019-01-20 | Bristol Myers Squibb Co | Polipeptidi antitela koji antagonizuju cd40 |
| JP6038920B2 (ja) * | 2011-08-23 | 2016-12-07 | ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム | 抗ｏｘ４０抗体およびそれを使用する方法 |
| JP6886816B2 (ja) | 2013-09-09 | 2021-06-16 | カニムガイド セラピューティックス アーベー | 免疫系調節薬 |
| GB201403775D0 (en) * | 2014-03-04 | 2014-04-16 | Kymab Ltd | Antibodies, uses & methods |
| JP2017165652A (ja) * | 2014-06-30 | 2017-09-21 | 国立大学法人東北大学 | 新規抗ヒトｏｘ４０リガンド抗体、及びこれを含む抗インフルエンザ薬 |
| AU2015301338C1 (en) * | 2014-08-04 | 2021-07-22 | Baylor Research Institute | Antagonistic anti-OX40L antibodies and methods of their use |
| US11554181B2 (en) | 2014-09-05 | 2023-01-17 | The University Of North Carolina At Charlotte | Tumor specific antibody conjugates and uses therefor |
| US9434785B1 (en) | 2015-04-30 | 2016-09-06 | Kymab Limited | Anti-human OX40L antibodies and methods of treating graft versus host disease with the same |
| LT3265123T (lt) * | 2015-03-03 | 2023-01-25 | Kymab Limited | Antikūnai, naudojimas ir būdai |
| US9512229B2 (en) | 2015-03-03 | 2016-12-06 | Kymab Limited | Synergistic combinations of OX40L antibodies for the treatment of GVHD |
| US9139653B1 (en) | 2015-04-30 | 2015-09-22 | Kymab Limited | Anti-human OX40L antibodies and methods of treatment |
| WO2016144650A1 (en) | 2015-03-06 | 2016-09-15 | Canimguide Therapeutics Ab | Immune system modulators and compositions |
| MY189692A (en) | 2015-05-07 | 2022-02-26 | Memorial Sloan Kettering Cancer Center | Anti-ox40 antibodies and methods of use thereof |
| IL299072A (en) | 2015-12-02 | 2023-02-01 | Memorial Sloan Kettering Cancer Center | Antibodies and methods of use thereof |
| DE102016105069A1 (de) | 2016-03-18 | 2017-09-21 | Eberhard Karls Universität Tübingen Medizinische Fakultät | Antivirale Immuntherapie durch Membranrezeptorligation |
| AU2016402264B2 (en) * | 2016-04-15 | 2024-08-22 | Pontificia Universidad Católica De Chile | Pharmaceutical composition for reducing the symptoms and disease of the respiratory infection caused by human metapneumovirus (HMPV), which comprises at least one agent that neutralises the function of the TSLP and/or TSLPR and/or OX40L and/or CD177 molecules, and a pharmaceutically acceptable excipient, and the use thereof |
| US9567399B1 (en) | 2016-06-20 | 2017-02-14 | Kymab Limited | Antibodies and immunocytokines |
| RU2769282C2 (ru) | 2016-06-20 | 2022-03-30 | Кимаб Лимитед | Анти-PD-L1 и IL-2 цитокины |
| CA3032897A1 (en) | 2016-08-09 | 2018-02-15 | Kymab Limited | Anti-icos antibodies |
| EP3534947A1 (en) | 2016-11-03 | 2019-09-11 | Kymab Limited | Antibodies, combinations comprising antibodies, biomarkers, uses & methods |
| CA3041340A1 (en) | 2016-11-09 | 2018-05-17 | Agenus Inc. | Anti-ox40 antibodies, anti-gitr antibodies, and methods of use thereof |
| GB201709808D0 (en) | 2017-06-20 | 2017-08-02 | Kymab Ltd | Antibodies |
| BR112020010137A2 (pt) | 2017-11-24 | 2020-10-13 | Eucure (Beijing) Biopharma Co., Ltd | anticorpos anti-ox40 e usos dos mesmos |
| GB201721338D0 (en) | 2017-12-19 | 2018-01-31 | Kymab Ltd | Anti-icos Antibodies |
| US11629189B2 (en) | 2017-12-19 | 2023-04-18 | Kymab Limited | Bispecific antibody for ICOS and PD-L1 |
| GB202012331D0 (en) * | 2020-08-07 | 2020-09-23 | Petmedix Ltd | Therapeutic antibodies |
| CN114437228B (zh) * | 2020-10-30 | 2024-02-06 | 中国科学院生物物理研究所 | 一种il-2与抗体亚单位构成的双功能融合蛋白 |
| JP7688150B2 (ja) * | 2020-12-09 | 2025-06-03 | エイチケー イノ．エヌ コーポレーション | 抗ＯＸ４０Ｌ抗体、抗ＯＸ４０Ｌ及び抗ＴＮＦαの二重特異性抗体、並びにこれらの用途 |
| AU2022326849A1 (en) * | 2021-08-10 | 2024-03-21 | Kymab Limited | Treatment of atopic dermatitis |
| CA3258958A1 (en) * | 2022-02-09 | 2023-08-17 | Petmedix Ltd | THERAPEUTIC ANTIBODIES |
| WO2025090570A1 (en) * | 2023-10-23 | 2025-05-01 | Abcellera Biologics Inc. | Anti-ox40l antibodies and methods of use |
| WO2025158009A1 (en) * | 2024-01-26 | 2025-07-31 | Almirall S.A. | Bispecific molecules and methods of treatment using the same |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5457035A (en) | 1993-07-23 | 1995-10-10 | Immunex Corporation | Cytokine which is a ligand for OX40 |
| US5821332A (en) | 1993-11-03 | 1998-10-13 | The Board Of Trustees Of The Leland Stanford Junior University | Receptor on the surface of activated CD4+ T-cells: ACT-4 |
| US6242566B1 (en) | 1994-02-10 | 2001-06-05 | Board Of Trustees Of The Leland Stanford Junior University | Ligand (ACT-4-L) to a receptor on the surface of activated CD4+ T-cells |
| JP3914342B2 (ja) | 1997-09-25 | 2007-05-16 | 武田薬品工業株式会社 | ｇｐ３４結合阻害物を有効成分として含有する医薬組成物 |
| US20030012781A1 (en) * | 2000-06-06 | 2003-01-16 | Anderson Darrell | Non-agonistic antibodies to human gp39, compositions containing, and therapeutic use thereof |
| FR2822846B1 (fr) | 2001-04-03 | 2004-01-23 | Technopharm | Procede de preparation et de selection d'anticorps |
| GB0123276D0 (en) | 2001-09-27 | 2001-11-21 | Imp College Innovations Ltd | Uses of agents that bind immune-system components |
| JP3926596B2 (ja) | 2001-09-28 | 2007-06-06 | 独立行政法人科学技術振興機構 | Ｏｘ４０ｌ遺伝子を導入した自己免疫疾患モデル非ヒト哺乳動物 |
| AU2002365814A1 (en) | 2001-12-18 | 2003-07-30 | J And J Research Pty Ltd | Method of treating asthma |
| IL164376A0 (en) | 2002-04-03 | 2005-12-18 | Applied Research Systems | Ox4or binding agents, their preparation and pharmaceutical compositions containing them |
| US20040136992A1 (en) | 2002-08-28 | 2004-07-15 | Burton Paul B. J. | Compositions and method for treating cardiovascular disease |
| US7291331B1 (en) | 2002-09-11 | 2007-11-06 | La Jolla Institute For Allergy And Immunology | Methods of treating OX40 medicated recall immune responses |
| CA2560889A1 (en) | 2004-03-23 | 2005-10-13 | Sanjay D. Khare | Monoclonal antibodies specific for human ox40l (cd 134l) |
| JP2006081061A (ja) | 2004-09-13 | 2006-03-23 | Alpine Electronics Inc | 音声出力装置及び音声／映像出力装置 |
| TWI380996B (zh) * | 2004-09-17 | 2013-01-01 | Hoffmann La Roche | 抗ｏｘ４０ｌ抗體 |
| MX2009009194A (es) | 2007-02-27 | 2009-10-08 | Genentech Inc | Anticuerpos ox40 antagonistas y su uso en el tratamiento de enfermedades inflamatorias y autoinmunes. |
-
2006
- 2006-12-15 RU RU2008129111/10A patent/RU2426744C2/ru not_active IP Right Cessation
- 2006-12-15 US US12/097,733 patent/US7812133B2/en active Active
- 2006-12-15 TW TW095147231A patent/TW200732349A/zh unknown
- 2006-12-15 ZA ZA200804868A patent/ZA200804868B/xx unknown
- 2006-12-15 CA CA002633602A patent/CA2633602A1/en not_active Abandoned
- 2006-12-15 EP EP06851330A patent/EP1973949A2/en not_active Withdrawn
- 2006-12-15 AU AU2006343459A patent/AU2006343459A1/en not_active Abandoned
- 2006-12-15 JP JP2008545995A patent/JP2009519718A/ja not_active Withdrawn
- 2006-12-15 WO PCT/US2006/062173 patent/WO2007133290A2/en not_active Ceased
- 2006-12-15 BR BRPI0621065-1A patent/BRPI0621065A2/pt not_active IP Right Cessation
- 2006-12-15 AR ARP060105564A patent/AR057253A1/es not_active Application Discontinuation
- 2006-12-15 KR KR1020087017186A patent/KR20080080639A/ko not_active Withdrawn
- 2006-12-15 CN CNA2006800529729A patent/CN101374865A/zh active Pending
-
2008
- 2008-05-29 IL IL191820A patent/IL191820A0/en unknown
- 2008-06-12 CR CR10069A patent/CR10069A/es not_active Application Discontinuation
- 2008-06-13 EC EC2008008543A patent/ECSP088543A/es unknown
- 2008-07-11 MA MA31104A patent/MA30153B1/fr unknown
- 2008-07-15 NO NO20083147A patent/NO20083147L/no not_active Application Discontinuation
-
2010
- 2010-07-12 US US12/834,748 patent/US20100272738A1/en not_active Abandoned